Form 4: Neuronetics Director Boosts Stake with 150K Share Purchase

Neuronetics Director and 10% owner Jorey Chernett acquired 150,000 shares of common stock in late March 2026, increasing his direct beneficial ownership.

Summary

• Jorey Chernett, a Director and 10% owner of Neuronetics, Inc. (STIM), purchased a total of 150,000 shares of common stock.
• On March 25, 2026, Mr. Chernett acquired 125,000 shares at a weighted average price of $1.40 per share, with prices ranging from $1.38 to $1.42.
• On March 26, 2026, an additional 25,000 shares were purchased at a price of $1.44 per share.
• Following these transactions, Mr. Chernett directly beneficially owns 8,893,276 shares of Neuronetics common stock.
• The transactions were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Significant insider buying by a director and 10% owner typically indicates high confidence in the company's prospects and valuation.

Positives

• A Director and 10% owner, Jorey Chernett, increased his direct beneficial ownership by 150,000 shares, signaling confidence in the company's future.
• The purchases were made at prices ranging from $1.38 to $1.44 per share, indicating a belief in value at these levels.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is an insider transaction report.

Management Comments

• Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director and significant shareholder, is generally viewed as a positive signal across industries. It often suggests that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are on the horizon. This transaction in the medical device sector could indicate confidence in Neuronetics' product pipeline or market position.

Comparison to Industry Standards

• Insider buying, especially by a director and 10% owner, is a strong indicator of management confidence, a trend observed positively across various industries, including technology and healthcare.
• While specific comparable companies or projects are not detailed in this Form 4, the magnitude of the purchase (150,000 shares) by a significant stakeholder like Jorey Chernett is generally considered a more robust signal than smaller, routine insider purchases seen in other firms.

Stakeholder Impact

• Shareholders may view this as a positive sign of confidence from a key insider, potentially increasing investor sentiment.
• Employees might interpret this as a positive indicator of the company's stability and future prospects.

Next Steps

• Jorey Chernett has undertaken to provide detailed price information for the purchased shares upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Recommendation

The significant purchase of 150,000 shares by a Director and 10% owner, Jorey Chernett, signals strong insider confidence in Neuronetics' valuation and future prospects. Such substantial insider buying is often a bullish indicator for seasoned investors, suggesting that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth. This action warrants a 'buy' recommendation based on the positive signal of insider conviction.

Keywords

Neuronetics, STIM, Insider Buying, Form 4, Jorey Chernett, Stock Purchase, Director Ownership, 10% Owner, Medical Devices, Neurology